1269055-85-7 Usage
General Description
Benzamide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluoro- is a chemical compound with the molecular formula C16H13F2NO3. It is a derivative of benzamide and contains both fluorine and hydroxyl functional groups. BenzaMide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluoro- is an organic molecule with potential pharmaceutical applications due to its structure and properties. It is commonly used in medicinal chemistry research and drug development efforts due to its potential biological activity and ability to interact with biological targets. BenzaMide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluoro- may have potential applications in the development of therapeutic agents and pharmaceutical drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 1269055-85-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,9,0,5 and 5 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1269055-85:
(9*1)+(8*2)+(7*6)+(6*9)+(5*0)+(4*5)+(3*5)+(2*8)+(1*5)=177
177 % 10 = 7
So 1269055-85-7 is a valid CAS Registry Number.
1269055-85-7Relevant articles and documents
From triclosan toward the clinic: Discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria
Gerusz, Vincent,Denis, Alexis,Faivre, Fabien,Bonvin, Yannick,Oxoby, Mayalen,Briet, Sophia,LeFralliec, Géraldine,Oliveira, Chrystelle,Desroy, Nicolas,Raymond, Cédric,Peltier, La?titia,Moreau, Fran?ois,Escaich, Sonia,Vongsouthi, Vanida,Floquet, Stéphanie,Drocourt, Elodie,Walton, Armelle,Prouvensier, Laure,Saccomani, Marc,Durant, Lionel,Genevard, Jean-Marie,Sam-Sambo, Vanessa,Soulama-Mouze, Coralie
, p. 9914 - 9928 (2013/01/16)
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically relevant Gram negative bacteria that is currently undergoing clinical trials.
